Jamie S. Barkin

We read Ma and colleagues' ( 1 ) article on the increasing incidence of mrCDI in the United States and Saini and Waljee's accompanying editorial ( 2 ) with great interest. Ma and colleagues showed an impressive trend of a 42.7% increase in CDI and a 188.8% increase in persons with multiple recurrent episodes of CDI between 2001 and 2012. We currently treat CDI unlike other infections because we do not routinely determine its sensitivity to antibiotic therapy.

We read with great interest the article by Masamune et al 1 regarding the role of long-term maintenance corticosteroids in patients with autoimmune pancreatitis (AIP).1 AIP is a steroid responsive disorder, which has two distinct entities with overlapping features, classified as type I and type II AIP. While type I AIP is a part of a spectrum of IgG4-related disease with extrapancreatic manifestations, type II is a pancreas-specific disease.

We read with great interest the article by Masamune et al1 regarding the role of long-term maintenance corticosteroids in patients with autoimmune pancreatitis (AIP).1 AIP is a steroid responsive disorder, which has two distinct entities with overlapping features, classified as type I and type II AIP. While type I AIP is a part of a spectrum of IgG4-related disease with extrapancreatic manifestations, type II is a pancreas-specific disease.